

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2020

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa
Medical College of Wisconsin

Paolo F. Caimi
Case Western Reserve University

Kirit M. Ardeshta
University College London Hospitals

Melhem Solh
Northside Hospital, Atlanta, GA

Carmelo Carlo-Stella
Humanitas University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Thapa, Bicky; Caimi, Paolo F.; Ardeshta, Kirit M.; Solh, Melhem; Carlo-Stella, Carmelo; Kahl, Brad S.; and Hamadani, Mehdi, "CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy." *Blood Advances*. 4, 16. 3850 - 3852. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9817

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Authors

Bicky Thapa, Paolo F. Caimi, Kirit M. Ardesbna, Melhem Solh, Carmelo Carlo-Stella, Brad S. Kahl, and Mehdi Hamadani

TO THE EDITOR:

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Bicky Thapa,¹ Paolo F. Caimi,² Kirit M. Ardeshtna,³ Melhem Solh,⁴ Carmelo Carlo-Stella,⁵ Brad S. Kahl,⁶ and Mehdi Hamadani¹

¹BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI; ²University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH; ³Department of Hematology, University College London Hospitals, NHS Foundation Trust, London, United Kingdom; ⁴Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA; ⁵Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Istituto di Ricovero e Cura a Carattere Scientifico, Humanitas University, Rozzano, Milan, Italy; and ⁶Oncology Division, Department of Medicine, Washington University, St. Louis, MO

Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), with aggressive clinical behavior.¹ Approximately 40% to 50% of DLBCL patients are refractory to or relapse after frontline chemoimmunotherapies.² Management of relapsed/refractory DLBCL is challenging, and treatment options include salvage therapy followed by autologous hematopoietic cell transplantation (autoHCT), in younger, chemosensitive patients.³ CD19-directed chimeric antigen receptor (CAR) modified T-cell therapy is another potentially curative option for patients with relapse after autologous hematopoietic cell transplantation or those with refractory disease.⁴ Axicabtagene ciloleucel and tisagenlecleucel are 2 anti-CD19 CAR T-cell treatments approved by the US Food and Drug Administration for relapsed/refractory DLBCL.^{5,6}

The CD19 antigen is an attractive target for immunotherapy in B-cell non-Hodgkin lymphoma. It is expressed during B-cell development only after B-lineage commitment and is thus not present on hematopoietic stem cells.⁷ CD19 expression is lost during terminal plasma cell differentiation but maintained in hematologic B-cell malignancies.⁷ Several clinical trials using monoclonal antibodies,⁸ antibody-drug conjugates (ADCs),⁹ and bispecific T-cell engagers targeting the CD19 antigen are ongoing in B-cell non-Hodgkin lymphoma. Studies investigating CD19-directed CAR T-cell therapies in aggressive lymphomas frequently excluded patients previously treated with CD19 targeting immunotherapies. Hence, the feasibility and efficacy of anti-CD19 CARs in lymphoma patients with prior CD19-directed immunotherapies are not known. Loncastuximab tesirine is an ADC comprising a humanized anti-CD19 monoclonal antibody stochastically conjugated to a pyrrollobenzodiazepine dimer toxin, SG3199.¹⁰ A phase 1 first-in-human study of loncastuximab tesirine demonstrated encouraging clinical activity in patients with relapsed/refractory DLBCL,⁹ and a phase 2 study recently finished patient accrual (#NCT03589469).

We sought to evaluate the outcomes of anti-CD19 CAR T-cell therapy in relapsed, refractory DLBCL previously treated with CD19-directed immunotherapy. Adult (age ≥ 18 years) DLBCL patients were identified from 2 multicenter, open-label studies of loncastuximab tesirine (phase 1: #NCT02669017 and phase 2: #NCT03589469), who subsequently received anti-CD19 CAR T-cell therapy. This retrospective analysis was approved by the institutional review board. Deidentified patient data were collected in collaboration with 6 academic medical centers (US centers = 4; United Kingdom = 1; Italy = 1) involved in the loncastuximab tesirine trials. Cytokine release syndrome was graded using Lee et al 2014 criteria,¹¹ and neurotoxicity was graded as per Common Terminology Criteria for Adverse Events, version 5.0.

A total of 14 DLBCL patients with disease relapsing or progressing after treatment with loncastuximab tesirine and subsequently undergoing CD19-directed CAR T-cell therapy were identified (Table 1). Among the 14 patients, 11 patients (79%) were male, and 13 patients (93%) were white. The median age was 58.5 years (range, 27 to 86). Ten had de novo DLBCL (germinal center B-cell-like = 4; non-germinal center B-cell = 2; not known = 4), and 4 patients had DLBCL transforming from indolent histologies (marginal zone lymphoma = 1; follicular lymphoma = 1; nodular lymphocyte predominant Hodgkin lymphoma = 1). Five patients (36%) had a high-intermediate international prognostic index at the time of diagnosis. c-MYC gene rearrangement was identified in 3 patients (21%) (1 patient had triple-hit lymphoma), whereas c-MYC status was unknown in 3 patients (21%). The median interval between diagnosis of DLBCL and initiation of loncastuximab tesirine was 21.5 months (range, 6.8 to 258). These patients received a median of 2 cycles (range, 1 to 7) of loncastuximab tesirine.

Table 1. Patient demographics and disease characteristics

	Patients (N = 14)
Age, median (range), y	58.5 (27-86)
Sex, n (%)	
Male	11 (79)
Female	3 (21)
Race, n (%)	
White	13 (93)
African American/black	1 (7)
Lymphoma subtype	
DLBCL*	10
Transformed DLBCL	4
IPI at diagnosis, n (%)	
Low (0, 1)	3 (21)
Low-intermediate (2)	3 (21)
High-intermediate (3)	5 (36)
Unknown	3 (21)
Advanced stage (III/IV) at diagnosis	4 (29)
c-MYC rearrangement, n (%)	
Yes	3 (21)
No	8 (57)
Unknown	3 (21)
Median interval between diagnosis and start of loncastuximab tesirine (range), mo	21.5 (6.8-258)
Best response to loncastuximab tesirine, n (%)	
Complete response	1 (7)
Partial response	5 (36)

Percentages may not add up to 100 due to rounding.
IPI, International Prognostic Index.
*One patient had mediastinal large B-cell lymphoma.

The antitumor response to loncastuximab tesirine in these 14 patients was as follows: 8 patients (57%) had refractory disease, 5 patients (36%) attained partial response, and 1 patient (7%) achieved a complete response (overall response rate [ORR] = 43%). All responding patients had progression of the disease before proceeding with CAR therapy.

Table 2 summarizes details of CAR T-cell therapy in these subjects. The median interval between loncastuximab tesirine and CAR T-cell therapy was 120 days (range, 22 to 600). Six patients received additional lines of therapy between loncastuximab tesirine and CAR T-cell treatment (median of 1 therapy line; range, 1 to 3). The CD19 expression was assessed by immunohistochemical staining on repeat biopsies in 10 patients (71%) in between loncastuximab tesirine and CAR administration. All 10 tested patients were positive for CD19 after ADC failure. This information was not available in 4 patients (29%). Before CAR T-cell administration, 13 patients had refractory or progressive disease, whereas 1 patient was in partial remission. All patients received standard lymphodepletion with fludarabine and cyclophosphamide before CAR T-cell therapy. The type of anti-CD19 CAR T-cell therapy received by the patients included axicabtagene ciloleucel (n = 5), tisagenlecleucel (n = 2), JCAR017 (n = 3), and investigational CARs targeting CD19 (n = 4; including 2 patients with CARs targeting dual antigens; Table 2).

Table 2. CAR T-cell therapy in DLBCL patients failing CD19-directed treatment

	Patients (N = 14)
CD19 expression on lymphoma cells after loncastuximab tesirine therapy, n (%)	
Positive	10 (71)
Not checked	4 (29)
Median interval between loncastuximab tesirine and CAR T-cell therapy (range), d	120 (22-600)
Additional therapy between loncastuximab tesirine and CAR T-cell therapy, n (%)	
Yes*	6 (43)
No	8 (57)
Disease status before CAR T-cell therapy, n (%)	
Refractory disease	5 (36)
Progressive disease	8 (57)
Partial remission	1 (7)
Flu/Cy lymphodepletion, n (%)	14 (100)
Type of CAR T-cell therapy, n (%)	
Axicabtagene ciloleucel	5 (36)
Tisagenlecleucel	2 (14)
Investigational targeting CD19†	4 (29)
JCAR017	3 (21)
Best response to CAR T-cell therapy, n (%)	
Complete response	6 (43)
Partial response	1 (7)
Refractory disease	7 (50)
CRS grade, n (%)	
None	6 (43)
1	3 (21)
2	4 (29)
3	1 (7)
ICANS grade, n (%)	
None	8 (57)
1	4 (29)
2	1 (7)
3	0 (0)
4	1 (7)

CRS, cytokine release syndrome; Flu/Cy, lymphodepletion with fludarabine/cyclophosphamide.

*Additional therapy between loncastuximab tesirine and CAR T-cell therapy included radiation alone (n = 3), radiation, ifosfamide/vinblastine/etoposide (n = 1), radiation; rituximab/methotrexate (n = 1), lenalidomide, anti-CD47 antibody, ibrutinib (n = 1).

†One patient each received a CD19/CD22-directed CAR, and a CD19/CD20-directed CAR. Neither patient responded to CAR treatment.

The median follow-up of survivors was 6 months (range, 3 to 22). Grade 1 to 2 cytokine release syndrome was common (n = 7; 50%). Grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) was identified in 4 patients (29%), and only 1 patient had grade 4 ICANS. Following CAR therapy, the best response at 3 months included 6 patients (43%) with a complete response and 1 patient (7%) with a partial response (ORR = 50%). Seven patients had refractory disease following CAR therapy. Five of 6 complete

